SOURCE: Benda Pharmaceutical, Inc.

October 02, 2007 12:55 ET

SiBiono, Gendicine® Receive Significant International Exposure in "Nature," "Nature Jobs" and "Chemistry World" Magazines

HUBEI PROVINCE, CHINA--(Marketwire - October 2, 2007) - Benda Pharmaceutical, Inc. ("Benda" or the "Company") (OTCBB: BPMA), a China-based pharmaceutical company producing traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer, announced today that it has recently received significant international media exposure through three acclaimed scientific publications: "Nature," "Nature Jobs" and "Chemistry World."

To read all articles on SiBiono and Gendicine®, visit http://bendapharma.com/in_the_news.cfm.

In the September 27, 2007 issue of "Nature," SiBiono and Gendicine® were spotlighted as a "headline-catching" example of Shenzhen, China's phenomenal growth and metamorphosis from "contract manufacturer to knowledge producer." Click here to read the article; if you cannot access the article through this link, the full URL can be found at the conclusion of this release.

In the September 27, 2007 issue of "Nature" sister publication "Nature Jobs," SiBiono and Gendicine® were the subject of a feature profile that offered the following facts, among many others:

--  "As of July 2007, Gendicine® has been administered to more than 6,000
    patients, about 400 of whom were Caucasian."
--  "While Gendicine® monotherapy is effective, it has significant
    synergistic effects in combination with chemotherapy, radiotherapy,
    surgery, or thermotherapy."
--  "Gendicine® is safe, with no evidence of extreme immune responses
    reported."
--  "At present, SiBiono's manufacturing capacity is about 150,000
    Gendicine® doses per year, which is likely to increase next year after
    the Company moves to its new RMB 200 million production facility."
    

Click here for the profile, or access the full URL at the conclusion of this release.

In addition to the two articles in the "Nature" family of publications, the August 31, 2007 issue of "Chemistry World" made public the following quote by Dr. Shanwen Zhang of Beijing Cancer Hospital, who chaired Gendicine®'s clinical trials: "'I think now we can confidently say Gendicine®'s efficacy is reliable." This statement was followed by confirmation from Dr. Jack Roth of the University of Texas Anderson Cancer Center, who first proposed the idea of using the p53 gene for cancer treatment "...that Gendicine® seems to have similar efficacy to p53 gene therapy he has studied in the United States."

About "Nature" Publications

"Nature" is the world's foremost weekly scientific journal and is the flagship journal for Nature Publishing Group (NPG). Launched in 1869, its original mission statement still leads the Group as it develops publications, explore opportunities arising from new technology and serve a growing audience of readers. NPG publishes journals and online databases across the life, physical and applied sciences and, most recently, clinical medicine. Content encompasses daily news from award-winning journalists, expert opinion and practical methodology, and more high impact research and reviews than any science publisher. Over 30 journals are published in association with prestigious academic societies. Visit www.Nature.com.

About "Chemistry World"

"Chemistry World" magazine is read by more than 43,000 scientists every month. With news analysis, features, opinion columns and the latest job advertisements, it's the best way to keep up to date with the chemical world. "Chemistry World" covers cutting edge research, international business news and government policy as it affects the chemical science community, plus the best product applications. Visit www.rsc.org/ChemistryWorld.

Articles

"Nature" Article:

http://files.shareholder.com/downloads/BPMA/151228937x4452657x134695/f99c51a2-304d-4e74-a700-37c2b42bb495/20071001--Enter the dragon-.pdf

"Nature Jobs" Profile:

http://files.shareholder.com/downloads/BPMA/151228937x4452657x134732/aa619997-63b4-4c7e-a63c-69e14a04956b/(20070930)Shenzhen_spotlight by Nature.pdf

About Benda Pharmaceutical, Inc.

Benda Pharmaceutical, Inc. (www.bendapharma.com), a China-based pharmaceutical company, is a pure play on explosive Chinese pharmaceutical spending and the global search for a cancer cure. Benda produces traditional Chinese and conventional medicines, as well as Gendicine®, the world's first commercialized gene therapy medicine for the treatment of cancer.

Benda Investor Resources

Fact Sheet:

http://files.shareholder.com/downloads/BPMA/151228937x4452657x111082/95430c49-a77a-43c9-89ad-d6cc75cffc59/FactSheet.pdf

PowerPoint Presentation:

http://files.shareholder.com/downloads/BPMA/151228937x4452657x111087/35a10e95-f328-45ad-81ab-529f6cc1af6d/Bendapresentation061107.pdf

Gendicine® Video:

http://play.rbn.com/play.asx?url=shareholder/shareholder/wmdemand/bendavideo.wmv&proto=mms?mswmext=.asx

FORWARD-LOOKING STATEMENTS

The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The safe harbor for forward-looking statements contained in the Securities Litigation Reform Act of 1995 protects companies from liability for their forward-looking statements if they comply with the requirements of the Act.

Contact Information